SLC31A1 and breast cancer: Recently, high SLC31A1 expression in breast cancer patients has led to poor overall survival, distant metastasis-free survival, and relapse-free survival (RFS), suggesting that SLC31A1 may be an unfavorable prognostic biomarker (Li X. et al., 2022).